Rep. Julia Letlow (R-La.) has disclosed a personal purchase of Amgen Inc. common stock (AMGN), according to a Periodic Transaction Report filed with the U.S. House of Representatives. The transaction, valued between $1,001 and $15,000, was made directly by the member of Congress and executed through a Merrill Lynch Investment Account (#025).
The trade itself took place on October 23, 2024, but the disclosure did not surface publicly until 292 days later. Under the STOCK Act, members of Congress and their staff are generally required to report transactions like this within 45 days of becoming aware of them. This filing arrived well outside that window, a fact that is noted here plainly and without any implication of wrongdoing or explanation as to the cause of the delay.
What the Filing Shows
The report identifies the asset simply as Amgen Inc. – Common Stock (AMGN), a biotechnology company traded under the ticker AMGN. The transaction type listed is a purchase, and the amount range disclosed, $1,001 to $15,000, is the standard bracketed figure used in STOCK Act filings rather than an exact dollar amount. Because the report does not include a specific price or share count, the precise size of the position cannot be determined from the disclosure alone.
Our internal classification tags this filing as a ‘congress buy’ signal, meaning it reflects an acquisition of shares by a sitting member of Congress rather than a sale or exchange. These classifications are drawn directly from the transaction type reported in the filing and are used on whoisbuyingnow.com to help readers track patterns in congressional trading activity over time.
Readers interested in how institutional money managers approach similar holdings may want to compare this individual disclosure with broader portfolio tracking, such as our coverage of BlackRock, Inc.’s quarterly 13F portfolio moves, which offers a different lens on how large asset managers position themselves across sectors including healthcare and biotech.
Periodic Transaction Reports like this one are self-certified by the filer and are made public as a matter of legal compliance, not as an endorsement or recommendation of any security. The filing does not state a rationale for the purchase, nor does it indicate whether Rep. Letlow’s office has commented on the timing of the disclosure. As with all STOCK Act filings tracked on this site, the information here reflects only what was reported: the asset, the transaction type, the date, the amount range, and the account through which it was held.